Top Stories
The findings could help refine patient selection and shape the design of future stroke trials.
One-man company Mithril developed a proof-of-principle for a bispecific antibody treatment for a rare muscular dystrophy in less than 18 months by using Claude to manage operations.
The assay detected tumour DNA at concentrations as low as 2.1 parts per million, and patients who tested positive had significantly shorter relapse-free survival.
The company said AI cut the pharmaceutical manufacturing batch-record review time by 89%, from nearly 26 hours to under three hours.
The two will combine molecular tumour profiling with existing clinical data to explore whether previously studied drugs could benefit different cancer populations.
Conference News
DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine (Scipher), a leader in immunology precision medicine, today announced the expected launch of an early physician access program for Pris...
O-Cyte 1 combines CBC testing and reviewable cell images with expandable throughput and service-ready design.DÜSSELDORF, Germany, Oct. 28, 2026 /CNW/ -- As AI-assisted morphology becomes more integrat...
Humanitas Global Health debuts at the American Association of Pharmaceutical Scientists’ 2026 PharmSci 360 congressCompany hosts a panel discussion on translating artificial intelligence innovations i...
Exploratory analysis presented at the ESMO Congress suggests changes in lactate dehydrogenase (LDH) measurements over time may complement imaging in assessing disease activity in glioblastomaCHANHASSE...
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenAUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA)...
